Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Chiara Cavallino, Alessandro Lupi, Roberta Rosso, Gioel Gabrio Secco, Angelo S. Bongo, Andrea Rognoni
Publikováno v:
Cardiovascular & Hematological Agents in Medicinal Chemistry. 13:4-9
Heart rate is a fundamental determinant of cardiac oxygen consumption and plays a pivotal role in the pathophysiology of chronic stable angina (CSA). Ivabradine selectively and specifically inhibits the sino-atrial If current, slowing selectively hea
Autor:
Alessandro Lupi, Fausto Castriota, Paolo Marino, Gioel Gabrio Secco, Francesca Mirabella, Rossella Fattori, Andrea Rognoni, Alberto Cremonesi, Giuseppe De Luca, Rosario Parisi
Publikováno v:
Cardiovascular & Hematological Agents in Medicinal Chemistry. 13:21-24
Since the first human catheterization performed by Forssman in 1929 angioplasty equipment and medical therapies have undergone considerable evolution and technical improvement allowing interventionalists to perform more complex procedures and solving
Autor:
Chiara Cavallino, Gioel Gabrio Secco, Francesco Rametta, Federico Nardi, Manuela Facchini, Angelo S. Bongo, Andrea Rognoni, Roberta Rosso, Alessia Veia, Sara Bacchini, Alessandro Lupi
Publikováno v:
Cardiovascular & Hematological Agents in Medicinal Chemistry. 13:10-13
Cardiovascular diseases and in particular coronary atherosclerotic disease are the leading cause of mortality and morbidity in the industrialized countries. Coronary atherosclerosis has been recognized for over a century and it was the subject of var
Autor:
A. Afşin Oktay, Sanjiv J. Shah
Publikováno v:
Current Cardiology Reviews
Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome associated with high rates of morbidi-ty and mortality. Due to the lack of evidence-based therapies and increasing prevalence of HFpEF, clinicians are often con-fron
Autor:
Thomas F. Whayne
Publikováno v:
Current Vascular Pharmacology. 15
Low-density lipoprotein cholesterol (LDL-C) is a well-established major cardiovascular (CV) risk factor supported by clinical evidence showing decreased atherosclerotic disease events when LDL-C is therapeutically lowered. A reasonable approach is to
Autor:
Carlos Cuellas, José M. Gonzalo-Orden, J. Francisco G. Marin, Armando Pérez de Prado, B. Martínez-Fernández, Alejandro Diego, José R. Altónaga, Marta Regueiro, Claudia Pérez-Martínez, Felipe Fernández-Vázquez
Publikováno v:
ResearcherID
In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior effi
Autor:
Christian H.P. Jansen, Boris Bigalke, Andreas Schuster, Eike Nagel, Marcus R. Makowski, René M. Botnar, Meinrad Gawaz
Publikováno v:
Current Vascular Pharmacology. 10:619-625
Coronary artery disease remains a major hazard within the western world despite early revascularisation and advanced medical therapy strategies. One of its major substrates is platelet activation and thrombus formation, triggering acute events such a
Publikováno v:
Current Vascular Pharmacology. 10:448-453
The glycoprotein (GP) IIb/IIIa receptor is critical to the process of platelet aggregation and thrombus formation as it serves as the final common pathway for platelet aggregation. For this reason, the development of GP IIb/IIIa inhibitors that block
Autor:
Lavoie, Stewart Dj
Publikováno v:
Current Vascular Pharmacology. 10:289-299
Since their initial discovery, endothelial progenitor cells (EPCs) have held tremendous promise for cell therapy for a variety of cardiovascular diseases including pulmonary hypertension. The clinical experience to date suggests that circulating or b
Publikováno v:
Current Vascular Pharmacology. 10:19-32
Patients with diabetes mellitus (DM) have a high prevalence of coronary artery disease (CAD), as diabetes is implicated in the formation of atherosclerotic plaque. Endothelial dysfunction is one of the precursor key steps in the development of athero